Functional systemic CD 4 immunity is required for clinical responses to PD ‐L1/ PD ‐1 blockade therapy
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The majority of lung cancer patients progressing from conventional therapies are refractory to PD-L1/PD-1 blockade monotherapy. Here, we show that baseline systemic CD4 immunity is a differential factor for clinical responses. Patients with functional systemic CD4 T cells included all objective responders and could be identified before the start of therapy by having a high proportion of memory CD4 T cells. In these patients, CD4 T cells possessed significant proliferative capacities, low co-expression of PD-1/LAG-3 and were responsive to PD-1 blockade ex vivo and in vivo. In contrast, patients with dysfunctional systemic CD4 immunity did not respond even though they had lung cancer-specific T cells. Although proficient in cytokine production, CD4 T cells in these patients proliferated very poorly, strongly co-upregulated PD-1/LAG-3, and were largely refractory to PD-1 monoblockade. CD8 immunity only recovered in patients with functional CD4 immunity. T-cell proliferative dysfunctionality could be reverted by PD-1/LAG-3 co-blockade. Patients with functional CD4 immunity and PD-L1 tumor positivity exhibited response rates of 70%, highlighting the contribution of CD4 immunity for efficacious PD-L1/PD-1 blockade therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical power analyses using G∗Power 3.1: tests for correlation and regression analyses
Faul, F., Erdfelder, E., Buchner, A., & Lang, A.-G. (2009) · Behavior Research Methods · doi:10.3758/brm.41.4.1149 · Cited by 37,615
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · cited 1×
“To assess whether CD4 T-cell profiling had prognostic value, the time elapsed from diagnosis to the start of immunotherapies was compared between G1 and G2 patient cohorts, as described (Le et al, 2015).”
MethodNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 1×
“As NSCLC patients with high PD-L1 tumor expression benefit from anti-PDL1/PD-1 blockade therapies (Borghaei et al, 2015), we assessed PD-L1 tumor expression and its association to responses in G1 and G2 patient cohorts for whom PD-L1 tumor expression could be determined.”
BackgroundSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“PD-L1/PD-1 blockade is demonstrating remarkable clinical outcomes since its first clinical application in human therapy (Brahmer et al, 2012; Topalian et al, 2012).”
BackgroundHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · cited 1×
“The causes for these distinct clinical outcomes are a subject for intense research (Topalian et al, 2016).”
BackgroundPersonalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · cited 1×
“Hence, CD4 T cells recognizing tumor neoepitopes contribute significantly to the efficacy of several types of immunotherapies in murine models and in cancer patients (Kreiter et al, 2015; Knocke et al, 2016; Sahin et al, 2017).”
BackgroundAhmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · cited 2×
“Several studies have been performed to monitor systemic dynamics of immune cell populations, some of them retrospectively and by high-throughput techniques (Hui et al, 2017; Kamphorst et al, 2017b; Krieg et al, 2018).”
BackgroundChemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246 · cited 1×
“PD-1 is expressed in antigen-experienced T cells and interferes with T-cell activation when engaged with PD-L1 (Chemnitz et al, 2004; Karwacz et al, 2011).”
BackgroundMutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015 · cited 6×
“Several studies have been performed to monitor systemic dynamics of immune cell populations, some of them retrospectively and by high-throughput techniques (Hui et al, 2017; Kamphorst et al, 2017b; Krieg et al, 2018).”
BackgroundResultInfluentialSystemic Immunity Is Required for Effective Cancer Immunotherapy
Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963 · cited 2×
“Indeed, the appearance of a specific murine subtype of CD4 T cell was the main correlator with efficacious responses by administration of anticancer cell immunoglobulins (Spitzer et al, 2017).”
BackgroundKamphorst, A. O., Pillai, R. N., Yang, S., Nasti, T. H., Akondy, R. S., Wieland, A., Sica, G. L., Yu, K., Koenig, L., Patel, N. T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705327114 · Cited by 854 · cited 6×
“Several studies have been performed to monitor systemic dynamics of immune cell populations, some of them retrospectively and by high-throughput techniques (Hui et al, 2017; Kamphorst et al, 2017b; Krieg et al, 2018).”
BackgroundResultInfluentialHigh-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F. J., Weber, L. M., Dummer, R., Robinson, M. D., Levesque, M. P., & Becher, B. (2018) · Nature Medicine · doi:10.1038/nm.4466 · Cited by 735 · cited 3×
“Several studies have been performed to monitor systemic dynamics of immune cell populations, some of them retrospectively and by high-throughput techniques (Hui et al, 2017; Kamphorst et al, 2017b; Krieg et al, 2018).”
BackgroundTumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Daud, A. I., Loo, K., Pauli, M. L., Sanchez-Rodriguez, R., Sandoval, P. M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87324 · Cited by 525
Lanna, A., Henson, S. M., Escors, D., & Akbar, A. N. (2014) · Nature Immunology · doi:10.1038/ni.2981 · Cited by 328
Self-citationA sestrin-dependent Erk–Jnk–p38 MAPK activation complex inhibits immunity during aging
Lanna, A., Gomes, D. C. O., Muller-Durovic, B., McDonnell, T., Escors, D., Gilroy, D. W., Lee, J. H., Karin, M., & Akbar, A. N. (2017) · Nature Immunology · doi:10.1038/ni.3665 · Cited by 284 · cited 3×
“T-cell percentages were quantified using FlowJo (Lanna et al, 2014, 2017).”
BackgroundMethodInfluentialSelf-citationTargeting dendritic cell signaling to regulate the response to immunization
Escors, D., Lopes, L., Lin, R., Hiscott, J., Akira, S., Davis, R. J., & Collins, M. K. (2008) · Blood · doi:10.1182/blood-2007-11-122408 · Cited by 116 · cited 4×
“To this end, we quantified CD4 T cells reactive to lung adenocarcinoma antigens using IFN-c-activated autologous monocyte-derived DCs as antigen presenting cells, as described (Escors et al, 2008).”
MethodInfluentialSelf-citation
Cited by
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Korman, A. J., Garrett-Thomson, S. C., & Lonberg, N. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 548
Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity
Baiden-Amissah, R. E. M., & Tuyaerts, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143586 · Cited by 30
Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer
Saillard, M., Cenerenti, M., Romero, P., & Jandus, C. (2021) · Vaccines · doi:10.3390/vaccines9050454 · Cited by 23
Metadata
- Authors
- Zuazo, M., Arasanz, H., Fernández‐Hinojal, G., García‐Granda, M. J., Gato, M., Bocanegra, A., Martínez, M., Hernández, B., Teijeira, L., Morilla, I., Lecumberri, M. J., Fernández de Lascoiti, A., Vera, R., Kochan, G., & Escors, D.
- Venue
- EMBO Molecular Medicine
- Published
- 2019-06-06
- Volume
- 11
- Issue
- 7
- Pages
- e10293-e10293
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2951492084
- Cited by
- 198
- References
- 19
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.